| Ytd | 11.01% | |
| 1y | -14.35% |
| Open | 5.91 | Prev Close | 5.92 | Low | 5.78 | High | 5.92 | Mkt Cap | 334.53M |
| Vol | 987.47K | Avg Vol | 1.38M | EPS | -1.21 | P/E | N/A | Forward P/E | -3.84 |
| Beta | 1.50 | Short Ratio | 10.79 | Inst. Own | 77.54% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 6.40 | 200-d Avg | 5.46 | 1yr Est | 16.75 |
ABEO News
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Oppenheimer analyst Jeff Jones maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and
Abeona Therapeutics reported Q2 revenues of $11.4m, treating five Zevaskyn patients, but missed anal
Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript
Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Belo
Abeona Therapeutics NASDAQ: ABEO reported second-quarter revenue growth from its ZEVASKYN cell thera
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.35) per share which missed the an
- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients tre
CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced
The Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NT
CLEVELAND, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-s
CLEVELAND, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced
NEW YORK, July 27, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating A
Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cel
CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-s
CLEVELAND, July 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced
CLEVELAND, June 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) w
CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced
Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript
Abeona Therapeutics NASDAQ: ABEO reported early commercial momentum for ZEVASKYN in the first quarte
Abeona Therapeutics Inc. (NASDAQ:ABEO) reported first-quarter earnings Wednesday before the market o
Abeona Therapeutics Inc. (NASDAQ: ABEO) reported first-quarter earnings Wednesday before the market
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.30) per share which beat the anal
- Three patients treated with ZEVASKYN ® in Q1 2026 - - QTC network expands to six sites, with two n
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) C
Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing gene
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-st
CLEVELAND, May 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) w
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.34) per share which beat the anal
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) w
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.10) per share which beat the anal
Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell
ABO-503 is composed of a functional human RS1 gene packaged in the novel AIM™ capsid AAV204. ABO-503
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) w
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) w
Oppenheimer analyst Andreas Argyrides maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperfo
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly earnings of $1.71 per share which beat the anal
BERWYN, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizab
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) w
Bio-Techne Corporation (NASDAQ:TECH) today announced that its Simple Western™ Technology played a ke